A Phase 1 Study of NKX019, a CD19 Chimeric Antigen Receptor Natural Killer (CAR NK) Cell Therapy, in Subjects with B-Cell MalignanciesMichael Dickinson, Brian T. Hill, Christian Bryant et al.|Blood|2021Cited by 19